4-Androstenediol

4-Androstenediol
Clinical data
Other names	Androst-4-ene-3β,17β-diol
Routes of; administration	Oral
Identifiers
	IUPAC name (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol;
CAS Number	1156-92-9 ;
PubChem CID	136297;
DrugBank	DB01526 ;
ChemSpider	120071 ;
UNII	G10EHA9I0D;
ChEMBL	ChEMBL195836 ;
CompTox Dashboard (EPA)	DTXSID5036505 ;
Chemical and physical data
Formula	C19H30O2
Molar mass	290.447 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C[C@H](CC[C@]34C)O;
	InChI InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,13-17,20-21H,3-10H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1 ; Key:BTTWKVFKBPAFDK-LOVVWNRFSA-N ;
	(what is this?) (verify)

4-Androstenediol, also known as androst-4-ene-3β,17β-diol, is an androstenediol that is converted to testosterone. The conversion rate is about 15.76%, almost triple that of 4-androstenedione, due to utilization of a different enzymatic pathway. There is also some conversion into estrogen, since testosterone is the metabolic precursor of the estrogens.

Quick Facts Clinical data, Other names ...

Close

4-Androstenediol is closer to testosterone structurally than 5-androstenediol, and has androgenic effects, acting as a weak partial agonist of the androgen receptor.^[1] However, due to its lower intrinsic activity in comparison, in the presence of full agonists like testosterone or dihydrotestosterone (DHT), 4-androstenediol has antagonistic actions, behaving more like an antiandrogen.^[1]

4-Androstenediol is very weakly estrogenic. It has approximately 0.5% and 0.6% of the affinity of estradiol at the ERα and ERβ, respectively.^[2]

Remove ads

Medical and commercial use

Patrick Arnold holds a 1999 patent on "Use of 4-androstenediol to increase testosterone levels in humans".^[3]

References

[1]
Chen F, Knecht K, Leu C, et al. (August 2004). "Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol". The Journal of Steroid Biochemistry and Molecular Biology. 91 (4–5): 247–57. doi:10.1016/j.jsbmb.2004.04.009. PMID 15336702. S2CID 53267316.
[2]
Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584.
[3]
"Use of 4-androstenediol to increase testosterone levels in humans". Archived from the original on 2011-03-18. Retrieved 2011-03-18.

This article about a steroid is a stub. You can help Wikipedia by expanding it.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Remove ads

[pmid15336702-1] [1]
Chen F, Knecht K, Leu C, et al. (August 2004). "Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol". The Journal of Steroid Biochemistry and Molecular Biology. 91 (4–5): 247–57. doi:10.1016/j.jsbmb.2004.04.009. PMID 15336702. S2CID 53267316.

[pmid9048584-2] [2]
Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584.

[3] [3]
"Use of 4-androstenediol to increase testosterone levels in humans". Archived from the original on 2011-03-18. Retrieved 2011-03-18.

[1]

[2]

[3]